Optimizing treatment of hypertension: assessment of efficacy of generic telmisartan - mirel®

Purpose of the study was to investigate antihypertensive, clinical, and organoprotective efficacy of generic telmisartan, Mirel® (Nikapharm, Uzbekistan), in patients with grade I-II arterial hypertension (AH). The study included 30 patients with mild to moderate hypertension (grade I-II arterial hypertension, ARCS, 2010). Mean age of patients was 51.42+10.92 years. All patients received Mirel® within 12 weeks in the mean daily dose of 86.1+48.9 mg. Echocardiography was performed in the M- and B-modes. Left ventricular myocardial mass (LVMM) was calculated by the Devereux formula. LVMM index (LVMMI) was calculated as ratio of LVMM to the body surface area. Endothelium-dependent vasodilation (EDVD) of the brachial artery was evaluated using reactive hyperemia test by Celermajer; intima-media complex thickness (IMT) of common carotid artery was measured by high-resolution ultrasonography (7.5 MHz). Renal function was determined by the level of microalbuminuria, serum creatinine and estimated glomerular filtration rate (GFR by the MDRD formula). 12-week Mirel ® monotherapy showed high antihypertensive efficacy of this drug in achieving the target levels of both SBP and DBP in 77% of patients. Organoprotective efficacy was characterized by a significant reduction in LVMM and LVMMI; the improvement of diastolic LV function and EDVD; significant reduction of IMT and microalbuminuria level; and increase in the levels of estimated GFR. The results showed high antihypertensive and organoprotective efficacy of generic telmisartan, Mirel ®, in patients with mild to moderate hypertension.